Synthesis and Biological and Structural Characterization of the Dual-Acting Peroxisome Proliferator-Activated Receptor α/γ Agonist Ragaglitazar
- 1 March 2003
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 46 (8) , 1306-1317
- https://doi.org/10.1021/jm021027r
Abstract
A new and improved synthesis of the peroxisome proliferator-activated receptor (PPAR) agonist ragaglitazar applicable for large-scale preparation has been developed. The convergent synthetic procedure was based on a novel enzymatic kinetic resolution step. The conformation of ragaglitazar bound to the hPPARγ receptor was quite different compared to the single-crystal structures of the l-arginine salt of ragaglitazar. In particular, the phenoxazine ring system had varying orientations. Ragaglitazar had high affinity for the hPPARα and -γ receptors with IC50 values of 0.98 and 0.092 μM, respectively. The lack of hPPARδ activity could be explained by the absence of binding in the tail-up pocket in the hPPARδ receptor, in contrast to the hPPARδ agonist GW2433, which was able to bind in both the tail-up and tail-down pockets of the receptor.Keywords
This publication has 31 references indexed in Scilit:
- Effects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical recordsClinical Therapeutics, 2002
- Novel Tricyclic-α-alkyloxyphenylpropionic Acids: Dual PPARα/γ Agonists with Hypolipidemic and Antidiabetic ActivityJournal of Medicinal Chemistry, 2002
- A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitusClinical Therapeutics, 2001
- Structure of the PPARα and -γ Ligand Binding Domain in Complex with AZ 242; Ligand Selectivity and Agonist Activation in the PPAR FamilyStructure, 2001
- (−)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(−)DRF 2725]: A Dual PPAR Agonist with Potent Antihyperglycemic and Lipid Modulating ActivityJournal of Medicinal Chemistry, 2001
- Cost-Effectiveness of Treating Hyperlipidemia in the Presence of DiabetesCirculation, 2000
- Fenofibrate and Rosiglitazone Lower Serum Triglycerides with Opposing Effects on Body WeightBiochemical and Biophysical Research Communications, 2000
- The PPARs: From Orphan Receptors to Drug DiscoveryJournal of Medicinal Chemistry, 2000
- A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma: effect of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker fatty rats.Diabetes, 1998
- Mechanism of Action of Fibrates on Lipid and Lipoprotein MetabolismCirculation, 1998